Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q2 2022 Results Conference Call July 28, 2022 4:30 PM ET

Company Participants

David Carey - Head, Investor Relations

Steven Sherman - Chairman & CEO

Scott Davis - President & Chief Operating Officer

Jerome Wong - interim Chief Financial Officer

Conference Call Participants

Swayampakula Ramakanth - H.C. Wainwright

Kyle Bauser - LakeStreet Capital

Operator

Hello, and welcome to the Ekso Bionics Q2 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to David Carey. Please go ahead.

David Carey

Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Steven Sherman, Chairman and Chief Executive Officer; Scott Davis, President and Chief Operating Officer; and Jerome Wong, Interim Chief Financial Officer. Earlier today, Ekso Bionics released financial results for the second quarter of 2022. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements.

All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For a list of description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. Ekso disclaims any intention or obligation, except as required by law, to update or revise any financial or operational projections, our regulatory outlook or other forward-looking statements whether because of new information, future events or otherwise, which speak only as of today, July 28, 2022.

I will now turn the call over to Ekso Bionics' Chairman and CEO, Steven Sherman.

Steven Sherman

Thank you, David, and thank you to everyone for joining us today. We achieved strong revenue growth in the second quarter, reflecting the continued execution by our team. We are successfully raising awareness of the benefits that our innovative EksoNR devices are bringing to patients. This is resulting in strong demand with inpatient rehabilitation facilities and network operators. And now with the recent clearance by the U.S. Food and Drug Administration, giving us the ability to market EksoNR with use with MS patients, we are poised to help a significantly larger patient population.